Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AstraZeneca

Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron

Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose. The follow-up analysis involved 26,400 individuals. Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated…

Benzinga

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK

AstraZeneca Settles Ultomiris-Related Patent Litigation With Chugai

Alexion Pharmaceuticals, a unit of AstraZeneca plc (NASDAQ: AZN), has entered into a settlement agreement with Chugai Pharmaceutical Co Ltd, resolving all patent disputes related to Ultomiris (ravulizumab).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Astrazeneca: Our Vaccine Helped Save More Than One Million Lives

In the global fight against "Covid-19”, AstraZeneca has become a household name for millions of people around the world. It has supplied over 2.7 billion doses of the vaccine globally, with approximately two-thirds going to low- and middle-income countries, according to Mene Pangalos Executive Vice-President, BioPharmaceuticals R&D. In a wide-ranging…

Asharq Al-Awsat

Europe Kickstarts Reviewing AstraZeneca Application For Its COVID Antibody

European Medicines Agency has started reviewing AstraZeneca Plc's (NASDAQ:AZN) application for antibody-based COVID-19 therapy but gave no timeline for a conclusion. Infections from COVID-19 are still rising in parts of the world, including Europe. On Tuesday, China posted a steep jump in daily COVID-19 infections, with new cases more than doubling from a…

Benzinga

Europe begins reviewing application for AstraZeneca COVID drug

Europe's drug regulator said on Tuesday it had begun reviewing AstraZeneca Plc's application for antibody-based COVID-19 therapy, a key step towards approval of the treatment in the region, but gave no timeline for a conclusion.

Reuters

Read news from The Economist, FT, and more,
with one subscription

FDA Declines To Approve AstraZeneca's Asthma Treatment For Chronic Nasal Condition

The FDA has declined to approve AstraZeneca Plc's (NASDAQ:AZN) asthma medicine, Fasenra (benralizumab), to treat chronic rhinosinusitis with nasal polyps, a condition characterized by benign growths that cause pain and stuffiness. The FDA has issued a complete response letter following AstraZeneca's application to extend the use of Fasenra and requested additional clinical data…

Benzinga

Counting vaccine donations as foreign aid will allow UK to cut £140m from budget

New international guidelines may even allow Britain and other western countries to claim back substantially more money than they paid for vaccine supplies

The Independent UK

Vaccine caused Tas man's death: Coroner

A Tasmanian father of four died from adverse effects of the AstraZeneca coronavirus vaccine, a coroner has found.

AAP

Blood Clot Risk After First AstraZeneca COVID-19 Shot Very Small - UK Study Shows

A large study into rare blood clots linked with AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine found

Benzinga

Clotting risk overhyped: studies show AstraZeneca safer than reported

Two new studies have found that the increased risk of blood clots associated with the AZ vaccine affected fewer than 3 in 1 million people.

Crikey

Latest data shows AstraZeneca blood clot risk extremely small

The latest research indicates the risks of blood clots from AstraZeneca are extremely small, with data coming out from millions of people around the world who have had the COVID-19 vaccine.

The Canberra Times

AstraZeneca Gaps Higher After Touting 'Historic' And Unexpected Win In Breast Cancer

AstraZeneca popped to a three-month high after the company touted a previously unheard-of result for its breast cancer treatment, Enhertu.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly acquired rare disease drug Ultomiris for a

Benzinga

AstraZeneca's Stock Gain After Enhertu Meets Primary Endpoint In HER2-Low Breast Cancer Setting

AstraZeneca plc (NASDAQ: AZN) said that

Asharq Al-Awsat

Iran Returns Donated Vaccines Because They Were Made in US

Iran has returned 820,000 doses of coronavirus vaccines donated by Poland because they were manufactured in the United States, state TV reported Monday. TV quoted Mohammad Hashemi, an official in the country’s Health Ministry, as saying that Poland donated about a million doses of the British-Swedish AstraZeneca vaccine to Iran.…

Daily Mirror

AZ Covid jab professor reveals vile anti-vax attacks forced him to get police protection

Professor Andrew Pollard was a part of the team behind the Oxford-Astrazeneca Covid jab which saved untold lives, despite his work he received a number of threats from anti-vaxxers and extremists

Get all your
news in one place.

100’s of premium titles.
One news app.

Bangkok Post

Vaccine side effects very rare, says DDC

Few side effects have been reported among the 120 million Covid-19 vaccine doses administered, according to the Department of Disease Control (DDC).

The Guardian - UK

Covid: South Korea reports more than 100,000 new cases for first time – as it happened

Latest updates: south Korean case numbers have risen in recent weeks due to Omicron

Benzinga

Short Shelf Life Of AstraZeneca's COVID-19 Shot Entangles Vaccine Rollout In Poorer Nations: Reuters

According to officials and internal World Health Organization documents reviewed by Reuters, the relativel

StockNews.com

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Reuters

Exclusive-Short AstraZeneca shelf life complicates COVID vaccine rollout to world's poorest

The Guardian - UK

Germany and Switzerland set to ease restrictions – as it happened

This blog is now closed.

Asharq Al-Awsat

Short AstraZeneca Shelf Life Complicates COVID Vaccine Rollout to World’s Poorest

The relatively short shelf life of AstraZeneca Plc's COVID-19 vaccine is complicating the rollout to the world's poorest nations, according to officials and internal World Health Organization documents reviewed by Reuters. It is the latest headache to plague the COVAX vaccine-sharing project, co-led by the WHO and aimed at getting…

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Office for National Statistics

World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.